
Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces
Findings from the pivotal phase 3 ARRECTOR trial of roflumilast foam 0.3% for treatment of psoriasis affecting the scalp and body were published in the journal JAMA Dermatology,1 according to a May 7 announcement from Arcutis. The company has submitted a …